Behçet’s Disease: A Complex and Rare Inflammatory Disorder

Behçet’s disease, or Behçet’s syndrome, is a rare, chronic inflammatory condition that predominantly affects blood vessels, causing a wide array of systemic symptoms. First described in 1937 by Turkish dermatologist Dr. Hulusi Behçet, the disease remains enigmatic, with its exact cause unknown. It is classified as an autoimmune disorder, wherein the immune system erroneously attacks healthy tissues. Genetic predisposition and environmental triggers, such as infections, are thought to contribute to its onset, especially in genetically susceptible individuals carrying the HLA-B51 gene marker.

Symptoms and Impact
Symptoms of Behçet’s disease are diverse, reflecting its multi-system involvement. Key manifestations include painful recurrent ulcers in the mouth and genitals, inflammatory skin lesions resembling acne or erythema nodosum, and uveitis—a severe eye inflammation that can lead to blindness if untreated. Other potential complications include arthritis, gastrointestinal ulceration, and central nervous system involvement, such as meningitis-like symptoms. Vascular complications, including blood clots, aneurysms, and arterial inflammation, can be life-threatening, underscoring the disease's potential severity.

Diagnostic Challenges
Diagnosing Behçet’s disease is inherently complex, as its symptoms overlap with other conditions like lupus and Crohn's disease. Clinicians rely on established diagnostic criteria, such as the International Criteria for Behçet's Disease (ICBD), which emphasize recurring oral ulcers and at least two other symptoms, including genital sores, skin lesions, or eye inflammation. Laboratory tests and imaging help exclude mimicking conditions but lack specificity for Behçet’s disease.

Management and Treatment
Treatment strategies are tailored to symptom severity and organ involvement. First-line options include corticosteroids for inflammation control and immunosuppressants like azathioprine or biologics such as TNF inhibitors for severe cases. Colchicine is often prescribed for joint and skin symptoms, while newer therapies, including interferon-alpha and IL-17 inhibitors, are under investigation. Early and aggressive treatment is critical to minimizing complications and preserving quality of life.

Epidemiology and Research
Behçet’s disease is more prevalent along the ancient Silk Road, affecting populations in Turkey, Iran, Japan, and China, though cases are reported globally. Its prevalence ranges from 1 in 15,000 in Turkey to fewer than 1 in 100,000 in Western countries. Current research focuses on understanding genetic pathways and immune dysregulation to develop targeted therapies, offering hope for improved outcomes in this challenging disorder.
Behçet’s Disease: A Complex and Rare Inflammatory Disorder

Dr. Hulusi Behçet

Anti-GBM Disease: A Rare Autoimmune Disorder Affecting Kidneys and Lungs

Anti-glomerular basement membrane (anti-GBM) disease, also known as Goodpasture syndrome, is a rare but severe autoimmune disorder that primarily targets the kidneys and lungs. The immune system mistakenly generates antibodies that attack the glomerular basement membrane in the kidneys and the alveolar basement membrane in the lungs. These membranes play crucial roles in filtration and gas exchange, making the effects of the disease potentially life-threatening.

In the kidneys, the immune system's antibodies attack the glomeruli, which are the small structures responsible for filtering waste products from the blood. This leads to inflammation and damage to the glomeruli, a condition known as glomerulonephritis. Patients with this condition often present with hematuria (blood in the urine) and proteinuria (excess protein in the urine), both of which are signs of kidney damage. If untreated, the disease can cause rapidly progressive glomerulonephritis, a condition that leads to acute kidney failure. The swift progression of the disease makes early diagnosis essential, as timely intervention can prevent long-term damage to the kidneys and reduce the risk of requiring dialysis or kidney transplantation.

In the lungs, anti-GBM antibodies attack the alveoli, the tiny air sacs responsible for gas exchange. This results in pulmonary hemorrhage, leading to symptoms such as hemoptysis (coughing up blood), shortness of breath, and chest pain. Lung involvement can be particularly dangerous as pulmonary hemorrhage can be sudden and severe, causing life-threatening respiratory failure if not treated immediately.

Treatment of anti-GBM disease is aimed at halting the production of harmful antibodies and removing them from the bloodstream. Immunosuppressive drugs, such as corticosteroids and cyclophosphamide, are commonly used to suppress the immune system's abnormal response. In conjunction, plasmapheresis, a procedure that filters the blood to remove antibodies, is often employed. When initiated early, this combination of treatments can significantly improve prognosis, helping to preserve kidney and lung function. Despite the aggressive nature of the disease, many patients can achieve remission with proper medical care, allowing them to maintain a good quality of life.
Anti-GBM Disease: A Rare Autoimmune Disorder Affecting Kidneys and Lungs

Hashimoto's Thyroiditis Overview

Hashimoto's thyroiditis, named after its discoverer Hakaru Hashimoto in 1912, is a complex condition where the body's immune system interacts with thyroid function. Originally thought to only cause hypothyroidism, Hashimoto's can present in various ways, such as hyperthyroidism, hypothyroidism, euthyroid goiter, or diffuse goiter. Essentially, it occurs because the immune system mistakenly targets the thyroid tissue as foreign.

This autoimmune condition involves both humoral and T-cell mediated immune responses, where antibodies attack the thyroid. The gradual onset of Hashimoto's results in ongoing inflammation within the thyroid, gradually impairing its function. On a microscopic level, Hashimoto's is marked by cellular hyperplasia, disruption of follicular cells, and infiltration of immune cells into the gland.

Although Hashimoto's can affect people of any age, it is more common in middle-aged women. The reasons for this gender and age tendency are still being investigated but may involve hormonal or genetic factors. Despite its subtle onset, early detection through thyroid function tests and imaging can help in timely management.

Managing Hashimoto's often requires a collaborative effort involving endocrinologists, immunologists, and primary care physicians. Treatment usually involves hormone replacement therapy to address thyroid hormone deficiencies. Additionally, medications that modulate the immune system may be prescribed to alleviate symptoms and temper the autoimmune response.

In summary, Hashimoto's thyroiditis demonstrates the intricate connection between the immune system and endocrine function. Understanding its underlying mechanisms and clinical presentations is crucial for accurate diagnosis and tailored treatment strategies. With ongoing research and medical advancements, progress is being made in enhancing the quality of life for individuals affected by this autoimmune disorder.
Hashimoto's Thyroiditis Overview

Eaton-Lambert syndrome

Lambert-Eaton syndrome, also known as Lambert-Eaton myasthenic syndrome, is a rare neuromuscular disorder in which IgG antibodies attacks the neuromuscular junctions — the areas where human nerves and muscles connect.

The weakness in patients with the Eaton-Lambert syndrome results from a presynaptic abnormality that results in a decrease in the quanta of acetylcholine released by the passage of the nerve impulse, although each quantum released is normal.

It seems that the Eaton-Lambert syndrome is caused by antibody-mediated autoimmune response that down-regulates the voltage-gated calcium channel and thereby impairs the calcium-dependent release of acetylcholine from the presynaptic active zone.

Muscle weakness in Eaton-Lambert syndrome tends to be symmetrical and is most pronounced in the lower extremities. Altered gait after prolonged walking usually is the initial symptom. This weakness may progress to inability to rise from a chair or walk up stairs.
Eaton-Lambert syndrome

Rheumatoid arthritis

Arthritis is a degenerative chronic disease that can affect any of the body’s joints. One of the very common type of the disease is rheumatoid arthritis, which is a chronic inflammatory disease involving the body’s immune system.

Because of the aggressiveness joint inflammation, the pain is much more sever and disabling than that of osteoarthritis.

Rheumatoid arthritis is the second most common arthritis found in older adults. Unlike osteoarthritis, rheumatoid arthritis is a systemic inflammatory and potentially destructive disorder of multiple joints.

The disease is affecting an estimated 2.1 million individuals in the United States or about 1 percent of the population. Like most autoimmune diseases, rheumatoid arthritis is more common in women. Other risk factors for rheumatoid arthritis include age greater than 50, smoking and relatives with rheumatoid arthritis.

Persons with rheumatoid arthritis feel systemically ill, with marked fatigue and a pervasive sense of overwhelming stiffness known as morning stiffness.

The Raynaud phenomenon and Sjogren syndrome are two inflammatory diseases commonly seen in rheumatoid arthritis patients.
Rheumatoid arthritis

What Is Lupus?

Lupus is a common name for the disorder known technically as lupus erythematosus. This formal name includes systemic lupus erythematosus (SLE) – where systemic means affecting the entire body or internal system.

People have used ‘lupus’ to describe a disease since the Middle Ages. Possibly the first recorded use of the word ‘lupus’ to identify a skin disease was in AD 855, when Herbernus, the archbishop of Tours, France, wrote in his Miracles of St. Martin.

The oldest evidence of a lupus-like disease is the mummy of a 14 year-old girl who died in AD 890 in Peru. Examination of the mummy shows evidence of hair loss, leathery  skin, lung disease and inflammation around the heart.

Systemic lupus erythematosus patients who have symptoms of achiness, fatigue, pain on taking a deep breath, fever, swollen glands, and signs of swollen joints or rashes but whose internal organs are not involve (for example, the heart, lungs, kidneys, or liver) are said to have non-organ-threatening disease.

Lupus erythematosus develops when the body becomes allergic to itself. The body overreacts to an unknown stimulus and makes too many antibodies, or proteins directed against body tissue. Thus, lupus is called an autoimmune disease.

Nearly four million Americans have lupus; that’s more than have AIDS, cerebral palsy, multiple sclerosis, sciklep0cell anemia, and cystic fibrosis combined.
What Is Lupus?

Autoimmune disorder

An autoimmune disease is a condition in which tissue injury is caused by T cell or antibody reactivity to self.

The immune activation may be initiated by infection, but then persist in the absence of any detectable microbial antigen. Autoimmune diseases are a family of more than 100 illnesses that develop when underlying defects in the immune system led to the body to attack its own organs, tissues and cells.

The diseases can be confusing and is probably when many people aren’t family with autoimmune disease or are unsure which illnesses fall into this category.

Furthermore, the names of these condition, which include Hashimoto’s thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, celiac disease and multiple sclerosis, among other don’t have the word ‘autoimmune’ in them.

Pathologic autoreactivty or autoimmune disease is often accompanied by credited immune competence, with an increased susceptibility to both infection and malignancy.

It is striking that whole each autoimmune disease individually affects only a small number of people. The prevalence of all autoimmune disease is approximately 5-7%.

Because a complete cure is not available for nearly every one of these 100 autoimmune diseases, patients face a lifetime of illness and treatment.

Because most of these diseases disproportionately afflict women, and are among the leading causes of death for young and middle-aged women, they impose a heavy burden on patents’ families and on society.
Autoimmune disorder